WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Medigene AG (FSE: MDG1, Prime Standard) have announced a three-year strategic partnership. The collaboration aims to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) targeting hard-to-treat tumors. This partnership merges Medigene’s advanced TCR generation and characterization expertise with WuXi Biologics’ industry-leading TCE platform and proprietary bispecific antibody platform, WuXiBody™.
Dr. Chris Chen, CEO of WuXi Biologics, expressed enthusiasm for the partnership, highlighting that it will enhance their research capabilities and support global partners in accelerating novel therapy development. “We believe this collaboration will ultimately lead to better cancer treatments worldwide,” he stated.
Selwyn Ho, CEO of Medigene, emphasized the potential for Medigene’s 3S TCRs to improve non-cellular therapies as well. “Partnering with WuXi Biologics allows us to apply our TCRs to new modalities, creating additional value for patients and shareholders,” he said.
WuXiBody™ is WuXi Biologics’ proprietary bispecific antibody platform, designed to overcome development barriers with high expression yield, stability, and ease of purification. This platform can significantly expedite the development process and reduce manufacturing costs by up to 18 months compared to other bispecific platforms.
WuXi Biologics
WuXi Biologics (2269.HK) is a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, providing comprehensive solutions for biologics discovery, development, and manufacturing. With over 12,000 employees across China, the U.S., Ireland, Germany, and Singapore, WuXi Biologics supports 698 client projects, including 24 in commercial manufacturing.
The company is committed to Environmental, Social, and Governance (ESG) principles, utilizing advanced biomanufacturing technologies and clean-energy sources. WuXi Biologics has established an ESG committee led by the CEO to guide and implement its sustainability strategy.
